Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma.
Integration of human papillomavirus (HPV) DNA into the host cell genome is a frequent event in cervical carcinogenesis, even though this phenomenon does not seem to be mandatory for cervical cancer development. Our objective was to describe the load and physical state of HPV type 16 (HPV16) DNA in a series of cervical samples representative of the natural history of cervical cancer. We used a combination of three real-time PCR assays targeting E6, E2, and albumin genes to calculate HPV16 load (E6 and albumin) and the E2/E6 ratio as a surrogate of integration. This method was applied to 173 HPV16-positive cervical samples. Results show that viral load increases with the lesion grade (from 102 HPV16 DNA copies per 10(3) cells in normal samples up to 56,354 copies per 10(3) cells in cancers), while E2/E6 ratio decreases (from 1 in normal samples down to 0.36 in cancers). We propose that, according to this technique, an HPV16 viral load of higher than 22,000 copies/10(3) cells or an E2/E6 ratio of lower than 0.50 allows the identification of women with prevalent high-grade lesions or worse with a high specificity. In conclusion, both viral load and E2/E6 ratio, used in combination with an appropriate cutoff value, are suitable to screen women with prevalent cervical intraepithelial neoplasia grade 2 or 3 or cancer. Therefore, these assays would be useful in addition to routine HPV testing to more accurately identify women with (pre)cancerous lesions.
Saunier
Maëlle
M
Laboratoire de Biologie Cellulaire et Moléculaire, IFR 133, Université de Franche-Comté, Centre Hospitalier Universitaire, Boulevard A. Fleming, 25030 Besançon cedex, France. jean_luc.pretet@univ-fcomte.fr
Monnier-Benoit
Sylvain
S
Mauny
Frédéric
F
Dalstein
Véronique
V
Briolat
Jenny
J
Riethmuller
Didier
D
Kantelip
Bernadette
B
Schwarz
Elisabeth
E
Mougin
Christiane
C
Prétet
Jean-Luc
JL
D017931:DNA Primers / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics / Q000302:isolation & purification*; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000235:genetics; D030361:Papillomavirus Infections / Q000473:pathology* / Q000821:virology*; D016133:Polymerase Chain Reaction / Q000379:methods; D012097:Repressor Proteins / Q000235:genetics; D013223:Statistics as Topic; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000821:virology*
D017931:DNA Primers; D004279:DNA, Viral; D004268:DNA-Binding Proteins; C054855:E2 protein, Human papillomavirus type 16; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D012097:Repressor Proteins
J Clin Microbiol. 2002 Mar;40(3):863-7
11880406
Int J Cancer. 2008 Jan 15;122(2):424-7
17893883
J Clin Virol. 2005 Mar;32 Suppl 1:S7-15
15753007
Am Fam Physician. 1995 Feb 1;51(2):434-40, 443-4
7840040
Virology. 2004 Jun 20;324(1):17-27
15183049
Lancet. 2004 Nov 6-12;364(9446):1678-83
15530628
N Engl J Med. 2003 Feb 6;348(6):518-27
12571259
Cancer Res. 2000 Nov 1;60(21):6027-32
11085523
Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2544-9
16284376
J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71
7658497
J Gen Virol. 1999 Jul;80 ( Pt 7):1725-1733
10423141
J Clin Microbiol. 2003 Feb;41(2):608-12
12574254
J Clin Virol. 2006 Mar;35(3):270-7
16214397
Gynecol Oncol. 2007 Sep;106(3):549-57
17568661
Int J Cancer. 2008 Jan 15;122(2):428-32
17893882
Int J Gynecol Pathol. 1993 Apr;12(2):186-92
8463044
Int J Cancer. 2002 Apr 1;98(4):590-5
11920620
Int J Cancer. 2004 Aug 20;111(2):278-85
15197783
J Virol. 1987 Apr;61(4):962-71
3029430
Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34
16950015
Br J Cancer. 2005 Jun 20;92(12):2195-200
15942630
Int J Cancer. 2007 Nov 15;121(10):2198-204
17657742
Int J Cancer. 2003 Sep 1;106(3):396-403
12845680
Clin Infect Dis. 2005 Feb 1;40(3):451-7
15668870
Cancer Res. 2006 Oct 15;66(20):10112-9
17047075
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3159-63
1313584
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
16030305
J Clin Microbiol. 2002 Mar;40(3):886-91
11880410
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1038-44
14578140
Lancet. 2001 Jun 9;357(9271):1831-6
11410191
J Clin Pathol. 2006 May;59(5):513-7
16484445
J Clin Microbiol. 2006 May;44(5):1755-62
16672403
Int J Cancer. 2007 Dec 15;121(12):2787-93
17722112
J Clin Microbiol. 2007 Mar;45(3):897-901
17229868
Diagn Mol Pathol. 2005 Jun;14(2):103-8
15905694
J Med Virol. 2006 Aug;78(8):1131-40
16789021
Gynecol Oncol. 2004 Mar;92(3):873-80
14984955
J Clin Virol. 2001 May;21(2):129-34
11378493
J Virol. 1989 Mar;63(3):1404-7
2536841
Int J Gynecol Pathol. 1998 Apr;17(2):146-53
9553812
J Clin Virol. 2004 Oct;31(2):140-7
15364271
J Clin Pathol. 2001 May;54(5):377-80
11328837
J Clin Pathol. 2003 Jul;56(7):532-6
12835300
Obstet Gynecol. 1998 Oct;92(4 Pt 2):727-35
9764690
Eur J Cancer. 2002 Jan;38(1):99-166
11750846
Int J Cancer. 2007 Aug 1;121(3):621-32
17405118
N Engl J Med. 1999 Nov 25;341(22):1633-8
10572150
Lancet Oncol. 2001 Sep;2(9):533-43
11905707
J Pathol. 1999 Sep;189(1):12-9
10451482
Clin Chem. 1999 Jul;45(7):982-6
10388473
J Virol. 2004 Nov;78(21):11451-60
15479788
Lancet. 2000 Jun 24;355(9222):2189-93
10881891
Gynecol Obstet Fertil. 2006 Jan;34(1):44-8
16406731
J Infect Dis. 1999 Nov;180(5):1415-23
10515798
J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
7791229